# Sergio Di Condojanni

> Sergio Di Condojanni is a seed investor at Angelini Pharma (Rome) backing Health Care and Women's. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Angelini Pharma](https://shizune.co/investors/profile/angelini-pharma-magyarorsz%C3%A1g)
- Location: Rome, Italy
- Total investments: 3
- Last investment: Jun 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/sergio-marullo-di-condojanni

Sergio Di Condojanni is a seed investor at Angelini Pharma in Rome focused on Health Care and Women's. Sergio Marullo di Condojanni is based out of Rome, Lazio and is the Chief Executive Officer of Angelini Pharma. Sergio previously worked at B20 Italy as a Member of the Advisory Board. Sergio Marullo di Condojanni attended Luiss Guido Carli University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Women's | 1 | 33% |
| Life Science | 1 | 33% |
| Therapeutics | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Series A | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 2 | 67% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rosso | Rosso is a startup dedicated to eliminating the blood shortage crisis in Italy by serving as a connective tissue in the blood supply chain, collaborating with schools, universities, donor associations, and hospitals. Our primary goal is to reduce patient wait times by increasing the number of donors, particularly young donors.Currently,Generation Z is not donating blood significantly; the average donor age is 45, while donation is allowed from 18 to 65 years old. Through innovative social media campaigns and a booking platform, we raise awareness among young people, encouraging them to book donations at nearby centers and providing instant chat access with hematologists to address their concerns.For companies, we offer a welfare service and sustainability membership that engages employees in health prevention and blood donation. We organize awareness webinars, donation days, and monitor employee health, providing impact reports. These activities are included in the company's sustainability report and contribute to B-Corp certification.Our third pillar involves management software for hospitals. We offer a plugin that optimizes blood stock management in hospitals by managing donor portfolios and the relationships between donors, associations, and hospitals. By knowing the blood stock levels, we can send automatic recalls or alerts when blood is needed and there are donors nearby ready to donate. With the help of AI, we can predict future blood stock needs, required blood types, and the timing of potential shortages. | $3.5M | Seed | Jun 10, 2026 |  |
| Freya Biosciences | Freya Biosciences is a clinical-stage women’s health company pioneering a new class of microbial immunotherapies. It is based in Copenhagen and Boston. | $38M | Series A | Dec 12, 2023 |  |
| Biovitae | Biovitae focuses on patent development in infection control and prevention, aiming to translate scientific discoveries into practical applications for human health and quality of life. | $3.3M | Seed | Nov 16, 2023 |  |

3 of 3 investments shown.

## Co-investors
- [CE-Ventures](https://shizune.co/investors/profile/ce-ventures) — VC Fund, 1 deal together
- [Corundum Systems Biology](https://shizune.co/investors/profile/corundum-systems-biology) — VC Fund, 1 deal together
- [Export and Investment Fund](https://shizune.co/investors/profile/export-and-investment-fund) — VC Fund, 1 deal together
- [H-FARM](https://shizune.co/investors/profile/h-farm) — VC Fund, 1 deal together
- [Indaco Venture Partners](https://shizune.co/investors/profile/indaco-venture-partners) — VC Fund, 1 deal together
- [OMX Ventures](https://shizune.co/investors/profile/omx-ventures) — VC Fund, 1 deal together

## About Angelini Pharma

VC Fund · Rome, Italy

Angelini Pharma specializes in healthcare, with particular expertise in the fields of mental health, pain and inflammation, and pediatrics.

4 contacts available at Angelini Pharma.

| Name | Title | Profile |
| --- | --- | --- |
| Sergio Di Condojanni | Chief Executive Officer | https://shizune.co/investors/profile/sergio-marullo-di-condojanni |
| Daniela Poggio | Executive Director Global Communications Angelini Pharma | https://shizune.co/investors/profile/daniela-poggio |
| Jacopo Andreose | CEO | https://shizune.co/investors/profile/jacopo-andreose |
| Rafał Kamiński | Chief Scientific Officer | https://shizune.co/investors/profile/rafa%C5%82-kami%C5%84ski |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Sergio Di Condojanni invest in?

Sergio Di Condojanni invests primarily in Health Care, Women's and Life Science startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sergio Di Condojanni last invest?

The most recent investment recorded for Sergio Di Condojanni closed in Jun 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co